ATE384725T1 - Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung - Google Patents

Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung

Info

Publication number
ATE384725T1
ATE384725T1 AT03810410T AT03810410T ATE384725T1 AT E384725 T1 ATE384725 T1 AT E384725T1 AT 03810410 T AT03810410 T AT 03810410T AT 03810410 T AT03810410 T AT 03810410T AT E384725 T1 ATE384725 T1 AT E384725T1
Authority
AT
Austria
Prior art keywords
pyrimido
pyrimidine derivatives
cancer effect
cancer
effect
Prior art date
Application number
AT03810410T
Other languages
English (en)
Inventor
Lee Apostle Mcdermott
Marek Kabat
Kin-Chun Luk
Pamela Rossman
Sung-Sau So
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE384725T1 publication Critical patent/ATE384725T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03810410T 2002-11-04 2003-10-27 Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung ATE384725T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42367002P 2002-11-04 2002-11-04

Publications (1)

Publication Number Publication Date
ATE384725T1 true ATE384725T1 (de) 2008-02-15

Family

ID=32312700

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03758072T ATE386744T1 (de) 2002-11-04 2003-10-27 Pyrimidoderivate mit antiproliferativer aktivität (ii)
AT03810410T ATE384725T1 (de) 2002-11-04 2003-10-27 Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03758072T ATE386744T1 (de) 2002-11-04 2003-10-27 Pyrimidoderivate mit antiproliferativer aktivität (ii)

Country Status (16)

Country Link
US (2) US7112676B2 (de)
EP (2) EP1560832B1 (de)
JP (2) JP2006513999A (de)
KR (4) KR100763299B1 (de)
CN (2) CN1711266A (de)
AR (2) AR041739A1 (de)
AT (2) ATE386744T1 (de)
AU (1) AU2003276190A1 (de)
BR (2) BR0315912A (de)
CA (2) CA2502180A1 (de)
DE (2) DE60318888T2 (de)
ES (2) ES2300609T3 (de)
MX (2) MXPA05004757A (de)
PL (2) PL376916A1 (de)
RU (2) RU2326882C2 (de)
WO (2) WO2004041821A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003903501A0 (en) * 2003-07-07 2003-07-24 Commonwealth Scientific And Industrial Research Organisation A method of forming a reflective authentication device
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2873127B1 (fr) 2004-07-13 2008-08-29 Omya Development Ag Procede de fabrication de particules pigmentaires autoliantes, seches ou en suspension ou dispersion aqueuses, contenant des matieres inorganiques et des liants
BRPI0514750A (pt) 2004-08-31 2008-06-24 Hoffmann La Roche derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
JP2008510690A (ja) * 2004-08-31 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及び医薬品としての使用
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
AU2007211684A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7H-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
JP2009531442A (ja) * 2006-03-29 2009-09-03 ノース・キャロライナ・ステイト・ユニヴァーシティ ６−ハロおよび６−アルコキシニコチン誘導体の合成および位置選択的置換
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
EP2318377B1 (de) * 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidinverbindungen und -zusammensetzungen sowie verfahren zu ihrer verwendung
CN102164900B (zh) 2008-09-25 2014-04-16 霍夫曼-拉罗奇有限公司 3-氨基-吲唑或3-氨基-4,5,6,7-四氢-吲唑衍生物
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
US8575179B2 (en) 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
HUP0800768A2 (en) 2008-12-18 2012-08-28 Bioblocks Magyarorszag Gyogyszerkemiai Es Fejlesztoe Kft 1,3-heterocycles condensed with monoterpene skeleton, their use and pharmaceutical compositions comprising such compounds
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20100318651A1 (en) * 2009-06-10 2010-12-16 Everis, Inc. Network Communication System With Monitoring
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
JP6576325B2 (ja) 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
DK3172213T3 (da) 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
WO2016023014A2 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AU2017291812B2 (en) 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
BR112019017741A2 (pt) 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
PE20212303A1 (es) * 2018-12-27 2021-12-10 Les Laboratoires Servier Sas Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352060A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) * 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
ES338687A1 (es) 1966-04-06 1968-04-01 Monsanto Co Procedimiento para obtener composiciones de fluidos funcio-nales.
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
AU7622698A (en) 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
KR200143829Y1 (ko) * 1996-12-30 1999-06-15 양재신 연료펌프 교환시 연료의 비산 방지구
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
CN1150195C (zh) * 1998-10-23 2004-05-19 霍夫曼-拉罗奇有限公司 双环氮杂环
KR100523120B1 (ko) 1999-10-21 2005-10-20 에프. 호프만-라 로슈 아게 Ｐ38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환
PL357494A1 (en) 1999-10-21 2004-07-26 F.Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
MY141144A (en) 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
BR0113628A (pt) 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxo-piridopirimidinas como inibidores de uma proliferação celular
ATE314370T1 (de) 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
AU2003270701B2 (en) * 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents

Also Published As

Publication number Publication date
MXPA05004756A (es) 2005-08-02
EP1560832B1 (de) 2008-01-23
ES2298622T3 (es) 2008-05-16
RU2005117341A (ru) 2006-03-10
CN1711266A (zh) 2005-12-21
EP1560829A1 (de) 2005-08-10
RU2326882C2 (ru) 2008-06-20
DE60318888T2 (de) 2009-01-08
CN1711264A (zh) 2005-12-21
DE60318888D1 (de) 2008-03-13
AU2003274086A1 (en) 2004-06-07
US7112676B2 (en) 2006-09-26
EP1560832A1 (de) 2005-08-10
WO2004041822A1 (en) 2004-05-21
RU2331641C2 (ru) 2008-08-20
BR0316001A (pt) 2005-09-13
JP2006507292A (ja) 2006-03-02
US20050075272A1 (en) 2005-04-07
ATE386744T1 (de) 2008-03-15
WO2004041821A1 (de) 2004-05-21
KR100774230B1 (ko) 2007-11-07
AU2003274086B2 (en) 2008-07-10
KR100763300B1 (ko) 2007-10-04
PL376924A1 (pl) 2006-01-09
US7129351B2 (en) 2006-10-31
CN100420688C (zh) 2008-09-24
KR100763299B1 (ko) 2007-10-04
KR100774231B1 (ko) 2007-11-07
US20040110773A1 (en) 2004-06-10
AR041739A1 (es) 2005-05-26
BR0315912A (pt) 2005-09-13
KR20050074540A (ko) 2005-07-18
DE60319260D1 (de) 2008-04-03
CA2502180A1 (en) 2004-05-21
KR20070087689A (ko) 2007-08-28
KR20070087657A (ko) 2007-08-28
KR20050074534A (ko) 2005-07-18
AR041738A1 (es) 2005-05-26
AU2003276190A1 (en) 2004-06-07
ES2300609T3 (es) 2008-06-16
EP1560829B1 (de) 2008-02-20
RU2005117340A (ru) 2006-02-27
MXPA05004757A (es) 2005-08-02
JP2006513999A (ja) 2006-04-27
CA2502182A1 (en) 2004-05-21
DE60319260T2 (de) 2009-03-05
PL376916A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
DE60318888D1 (de) Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
IS8406A (is) 5,7-díamínópýrasóló [4,3-d] pýrimidín með PDE-5 hindrandi virkni
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
DK1797099T3 (da) Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
HUS1500055I1 (hu) HIV-gátló pirimidinszármazékok
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
DK1487805T3 (da) Pyrimidinderivater
IL185912A0 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
MA28824B1 (fr) Derives de pyrimidine
IS7872A (is) Pýrrólópýrimidín afleiður
ATE388713T1 (de) 4-amino-6-phenyl-pyrrolo(2,3-d)pyrimidin derivate
DE60311101D1 (de) 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido und 2,3-dihydro-2h-pyrrolo (2,1-b)-chinazolinon-derivate
MA28813B1 (fr) Derives de pyrimidine
DK1761542T3 (da) Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
NO20053748D0 (no) Pyrrolopyridazinderivater.
DK1622880T3 (da) Substituerede dihydroquinazoliner med antivirale egenskaber
DE602004029045D1 (de) Pyrrolo [3,4-c] pyrazole derivate mit kinase hemmender wirkung
DE60206946D1 (de) Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen
NO20043565L (no) Heteroaryl-substituerte 2-pyridinyl- og 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater.
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
ATE326467T1 (de) Imidazo 1,2-aöpyridine
IL169318A0 (en) Pyrimidines, methods for the production thereof, and use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1560832

Country of ref document: EP

REN Ceased due to non-payment of the annual fee